Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.45 |
| ▸ | PPARG | P37231 | 6/20 | 0.45 |
| ▸ | PPARD | Q03181 | 6/20 | 0.45 |
| ▸ | PPARA | Q07869 | 6/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | FABP4 | P15090 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16061965 | 1.00 | KMT2A (0.50) | KMT2AMAPTCES2CES1HAO1 | |
| Propane SCHEMBL322960 | 0.98 | KMT2A (0.48) | KMT2AMAPTCES2CES1HAO1 | |
| Propane SCHEMBL743689 | 0.98 | KMT2A (0.48) | KMT2AMAPTCES2CES1HAO1 | |
| Hydrochloric Acid SCHEMBL27720432 | 0.98 | KMT2A (0.48) | KMT2AMAPTCES2CES1HAO1 | |
| Propane SCHEMBL29226175 | 0.98 | KMT2A (0.48) | KMT2AMAPTCES2CES1HAO1 | |
| SCHEMBL2905137 | 0.90 | FAAH (0.58) | KMT2AMAPTPPARGPPARDPPARA | |
| Propane SCHEMBL28144123 | 0.88 | FAAH (0.57) | KMT2AMAPTPPARGPPARDPPARA | |
| Propane SCHEMBL741627 | 0.88 | FAAH (0.57) | KMT2AMAPTPPARGPPARDPPARA | |
| Propane SCHEMBL26102539 | 0.87 | FAAH (0.55) | KMT2AMAPTPPARGPPARDPPARA | |
| Phosphoric Acid SCHEMBL1223979 | 0.84 | FABP3 (0.54) | KMT2AMAPTPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294450-B1 | METHODS FOR PREPARATION OF PLASMID DNA/LIPID PARTICLES WITH DEFINED SIZE FOR IN VITRO AND IN VIVO TRANSFECTION | UNIV JOHNS HOPKINS (US) | 2026-02-04 | — | — | EP | claimed |
| US-20240115513-A1 | METHODS FOR PREPARATION OF PLASMID DNA/LIPID PARTICLES WITH DEFINED SIZE FOR IN VITRO AND IN VIVO TRANSFECTION | THE JOHNS HOPKINS UNIVERSITY | 2024-04-11 | — | — | US | claimed |
| EP-4294450-A1 | METHODS FOR PREPARATION OF PLASMID DNA/LIPID PARTICLES WITH DEFINED SIZE FOR IN VITRO AND IN VIVO TRANSFECTION | The Johns Hopkins University (US) | 2023-12-27 | — | — | EP | claimed |
| WO-2022177977-A1 | METHODS FOR PREPARATION OF PLASMID DNA/LIPID PARTICLES WITH DEFINED SIZE FOR IN VITRO AND IN VIVO TRANSFECTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-08-25 | — | — | WO | claimed |
| EP-2925303-A1 | PROSTACYLIN COMPOSITIONS AND METHODS FOR USING THE SAME | Insmed Incorporated (US) | 2015-10-07 | — | — | EP | claimed |
| WO-2014085813-A1 | PROSTACYLIN COMPOSITIONS AND METHODS FOR USING THE SAME | INSMED INCORPORATED (US) | 2014-06-05 | — | — | WO | claimed |
| US-12616678-B2 | Methods to of aldehyde dehydrogenases for treatment of cancer | THE PENN STATE RESEARCH FOUNDATION (PA) | 2026-05-05 | — | — | US | disclosed |
| US-20260060944-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHIH KUEI CHUNG (TW) | 2026-03-05 | — | — | US | disclosed |
| US-12551434-B2 | Zwitterionic polymer particle compositions and related methods | WAYNE STATE UNIVERSITY (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4294450-B1 | METHODS FOR PREPARATION OF PLASMID DNA/LIPID PARTICLES WITH DEFINED SIZE FOR IN VITRO AND IN VIVO TRANSFECTION | UNIV JOHNS HOPKINS (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250387367-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | PENN STATE RES FOUND (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250312430-A1 | COMPOSITIONS OF LIPID NANOPARTICLES FOR PLASMID DNA DELIVERY TO THE LIVER AND METHODS FOR PREPARING THE SAME | THE JOHNS HOPKINS UNIVERSITY | 2025-10-09 | — | — | US | disclosed |
| EP-4499045-A1 | COMPOSITIONS OF LIPID NANOPARTICLES FOR PLASMID DNA DELIVERY TO THE LIVER AND METHODS FOR PREPARING THE SAME | The Johns Hopkins University (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-1001750-B1 | STABLE PARTICULATE COMPLEXES WITH NEUTRAL OR NEGATIVE GLOBALE CHARGE OF LAMELLAR STRUCTURE | CEVA SANTE ANIMALE (FR) | 2004-09-22 | — | — | EP | disclosed |
| EP-1404298-A2 | A METHOD FOR PREPARATION OF VESICLES LOADED WITH BIOLOGICAL MATERIAL AND DIFFERENT USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003000227-A2 | A METHOD FOR PREPARATION OF VESICLES LOADED WITH BIOLOGICAL MATERIAL AND DIFFERENT USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-01-03 | — | — | WO | disclosed |
| US-6096335-A | COMPLEX CONTAINING LIPID | BIOVECTOR THERAPEUTICS, S.A. (FR) | 2000-08-01 | — | — | US | disclosed |
| EP-1001750-A1 | STABLE PARTICULATE COMPLEXES WITH NEUTRAL OR NEGATIVE GLOBALE CHARGE OF LAMELLAR STRUCTURE | Biovector Therapeutics S.A. (FR) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006026-A9 | STABLE PARTICULATE COMPLEXES WITH NEUTRAL OR NEGATIVE GLOBAL CHARGE OF LAMELLAR STRUCTURE | BIOVECTOR THERAPEUTICS SA (FR) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999006026-A1 | STABLE PARTICULATE COMPLEXES WITH NEUTRAL OR NEGATIVE GLOBAL CHARGE OF LAMELLAR STRUCTURE | BIOVECTOR THERAPEUTICS (S.A.) (FR) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060944-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | LETM1, MCU, TFAM | KMT2A 2146/4885MAPT 3451/4885CES2 3531/4885 |
| US-20250387367-A1 | METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER | ALDH3A1, ALDH2, ADH1C | KMT2A 2357/4885MAPT 4736/4885CES2 96/4885 |
| US-20250312430-A1 | COMPOSITIONS OF LIPID NANOPARTICLES FOR PLASMID DNA DELIVERY TO THE LIVER AND METHODS FOR PREPARING THE SAME | STAT6, CD4, NFATC1 | KMT2A 2112/4885MAPT 3597/4885CES2 3078/4885 |
| US-12616678-B2 | Methods to of aldehyde dehydrogenases for treatment of cancer | ALDH1A1, ALDH3A1, ADH1C | KMT2A 777/4885MAPT 4198/4885CES2 124/4885 |
| US-12551434-B2 | Zwitterionic polymer particle compositions and related methods | IAPP, GIPR, INSR | KMT2A 3391/4885MAPT 1706/4885CES2 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.